RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
is_a (e.g. skeletal muscle fibre is_a muscle fibre) part_of (e.g. muscle fibre part_of muscle) develops/derives_from (e.g.myoma cell develops/derives_from muscle fibre) related_to (description of more general relationships between terms which are not covered by the other ones) Most of the terms are clearly associated with specific organisms, organs, tissues, or cell types. There are several identical designations for tissues both in plants and animals, e.g. “epidermis”. To distinguish between those tissue terms and to classify them correctly into BTO for plant tissues the prefix “plant” is placed before the term, e.g. “plant epidermis”. More than 80% of the tissue terms have definitions that describe the meaning and context. These definitions are obtained from i.e. medical dictionaries and cell line databases (Webster's Dictionary, DSMZ).
==== Manufacturing process ==== The process for making the americium used in the buttons on ionization-type smoke detectors begins with americium dioxide. The 241AmO2 is thoroughly mixed with gold, shaped into a briquette, and fused by pressure and heat at over 1,470 °F (800 °C). A backing of silver and a front covering of gold (or an alloy of gold or palladium) are applied to the briquette and sealed by hot forging. The briquette is then processed through several stages of cold rolling to achieve the desired thickness and levels of radiation emission. The final thickness is about 0.008 inches (0.20 mm), with the gold cover representing about one percent of the thickness. The resulting foil strip, which is about 0.8 inches (20 mm) wide, is cut into sections 39 inches (1 m) long. The sources are punched out of the foil strip. Each disc, about 0.2 inches (5.1 mm) in diameter, is mounted in a metal holder, usually made of aluminium. The holder is the housing, which is the majority of what is seen on the button. The thin rim on the holder is rolled over to completely seal the cut edge around the disc.
== Perinatal environment == Autism is associated with some perinatal and obstetric conditions. Infants that are born pre-term often have various neurodevelopmental impairments related to motor skills, cognition, receptive and expressive language, and socio-emotional capabilities. Pre-term infants are also at a higher risk of having various neurodevelopmental disorders such as cerebral palsy and autism, as well as psychiatric disorders related to attention, anxiety, and impaired social communication. It has also been proposed that the functions of the hypothalamic-pituitary-adrenal axis and brain connectivity in pre-term infants may be affected by NICU-related stress resulting in deficits in emotional regulation and socio-emotional capabilities. A 2019 analysis of perinatal and neonatal risk factors found that autism was associated with abnormal fetal positioning, umbilical cord complications, low 5-minute Apgar score, low birth weight and gestation duration, fetal distress, meconium aspiration syndrome, trauma or injury during birth, maternal hemorrhaging, multiple birth, feeding disorders, neonatal anemia, birth defects/malformation, incompatibility with maternal blood type, and jaundice/hyperbilirubinemia. These associations do not denote a causal relationship for any individual factor. There is growing evidence that perinatal exposure to air pollution may be a risk factor for autism, although this evidence has methodological limitations, including a small number of studies and failure to control for potential confounding factors.
Southern Rhodesia's fighting contributions in Britain and western Europe were primarily in the air, as part of the much larger Allied forces. Rhodesian pilots and Allied airmen trained in the colony's flying schools participated in the defence of Britain throughout the war, as well as in the strategic bombing of Germany and other operations. Rhodesia provided the only RAF flying ace of the Norwegian Campaign of April–June 1940, Squadron Leader Caesar Hull. Later that year "The Few", the Allied airmen of the Battle of Britain, included three pilots of Southern Rhodesian birth—Hull, Pilot Officer John Chomley and Flight Lieutenant John Holderness—of whom two, Hull and Chomley, lost their lives. Two of the RAF's three Rhodesian squadrons, Nos. 44 and 266, operated from England during the war. No. 266 (Rhodesia) Squadron, a fighter squadron based in Cambridgeshire for most of the duration, was initially only nominally Rhodesian, being manned by a mixture of British and Commonwealth personnel, but it received more airmen from the colony gradually and was virtually all Rhodesian by August 1941. Initially flying Spitfires, it switched to Typhoons in early 1942. It took as its motto the Sindebele word Hlabezulu ("Stabber of Skies") and first went into action over Dunkirk on 2 June 1940, after which it fought in the Battle of Britain. The squadron's duties thereafter included patrolling, protecting convoys, sweeping around northern France and the Belgian and Dutch coasts, and escorting bombing raids over France and the Rhine. No.
Sources: en.wikipedia.org
There is no curative treatment. The disease remains progressive and fatal. Current treatment is aimed towards improving mitochondrial function through both pharmacological and non-pharmacological methods. Multiple case studies have suggested that implementation of the Ketogenic diet may help reduce the incidence of stroke-like episodes associated with MELAS, one of the most common clinical features. Ketogenic diet therapy helps with the clearance of reactive-oxygen species (ROS), which commonly accumulate and harm the mitochondria in MELAS. Other supplementation treatments have been studied:
PET imaging with oxygen-15 indirectly measures blood flow to the brain. In this method, increased radioactivity signal indicates increased blood flow which is assumed to correlate with increased brain activity. Because of its two-minute half-life, oxygen-15 must be piped directly from a medical cyclotron for such uses, which is difficult. PET imaging with FDG takes advantage of the fact that the brain is normally a rapid user of glucose. Standard FDG PET of the brain measures regional glucose use and can be used in neuropathological diagnosis. Brain pathologies such as Alzheimer's disease greatly decrease brain metabolism of both glucose and oxygen in tandem. Therefore FDG PET of the brain may also be used to successfully differentiate Alzheimer's disease from other dementing processes, and also to make early diagnoses of Alzheimer's disease. The advantage of FDG PET for these uses is its much wider availability. In addition, some other fluorine-18 based radioactive tracers can be used to detect amyloid-beta plaques, a potential biomarker for Alzheimer's in the brain. These include florbetapir, flutemetamol, Pittsburgh compound B (PiB) and florbetaben. PET imaging with FDG can also be used for localization of "seizure focus". A seizure focus will appear as hypometabolic during an interictal scan. Several radiotracers (i.e.
Leroy-Beaulieu was born in Rome. After spending her childhood in Italy where her father, Philippe Leroy, worked in the local film industry, she went to Paris at 16 to study drama against the advice of her parents; her father especially tried to keep her from pursuing a career that followed in his footsteps but was unsuccessful. After appearing on the stage, Leroy-Beaulieu made her screen début in Roger Vadim's 1983 comedy-drama film Surprise Party. The following year, she played Fauve Mistral in the 1984 mini-series version of Judith Krantz's novel Mistral's Daughter. In 1985, Leroy-Beaulieu played her first major screen role (and earned a nomination for the César Award for Most Promising Actress), playing the distraught mother in the Academy Award for Best Foreign Film-nominated comedy Trois hommes et un couffin (Three Men and a Cradle). The success of Coline Serreau's comedy helped her film career and a string of parts in costume films followed such films as Andrzej Wajda's Les Possédés in 1988, Philippe Le Guay's Les Deux Fragonard, and Robert Enrico's and Richard T. Heffron's La Révolution française (Mademoiselle Leroy-Beaulieu acted out the role of Charlotte Corday in the latter production), whose release in 1989 was timed to coincide with celebrations for the bi-centenary of the 1789 Revolution. Leroy-Beaulieu starred in the title role of the French film Natalia, which was screened at the 1988 Cannes Film Festival.
== Research == Roy's researches during his stint in the US was on protein folding and nuclear magnetic resonance studies of DNA and those researches identified the first hydropathy model which helped in predicting the exteriors and interiors of proteins by analyzing sequence information. He is also reported to have performed the complete assignment of a nucleic acid imino proton spectra using Nuclear Overhauser effect, regio-specific isotope labeling of sugars in nucleic acids and working along with Ad Bax and R. H. Griffey, developed an indirect 2D-NMR detection method, all reported to be for the first time. Later focusing his attention on bacteriophage lambda, he studied the gene expression of the bacterial virus using its operator-repressor system. Through his collaborative work with Sankar Adhya in 1998, he elucidated the role of differential contact in the transcription regulation mechanism and demonstrated the theory in many genetic regulatory circuits. His current work is focused on peptide therapeutics and he holds patents for some of his work. Roy has published his research work through a number of articles published in peer-reviewed journals and ResearchGate, an online repository of scientific papers, has listed 155 of them. He is the Co-author of "Chemical Biology of the Genome" published by Elsevier/AP. He is a joint editor of Subcellular Biochemistry, volume on Proteins: Structure, Function, and Engineering published by Plenum Press, New York, USA and Protein-Protein interaction Regulators published by Royal Society of Chemistry, UK.
Aurora is one of the most ancient districts which developed out of the medieval city walls, north of the historical city centre. It stretches from downtown northern boundaries in Corso Regina Margherita (an extended and important thoroughfare of Turin) up to Corso Vigevano and Corso Novara in the North Side (namely the old excise boundary until the early 20th century); the western boundary is Corso Principe Oddone (now part of the Spina Centrale boulevard) and the eastern border is the River Dora. The district was named Aurora after the so-called Cascina Aurora, an old farmstead lying north of the River Dora, right at the intersection between Corso Giulio Cesare and Corso Emilia. The farmstead has long been demolished and the area has been converted to office buildings, hosting the Turinese textile company Gruppo Finanziario Tessile (GFT) headquarters until the early 21st century. The historical hub of the district is Borgo Dora (The 'Dora Borough'), a small neighbourhood next to Porta Palazzo and enclosed by Corso Regina Margherita, Via Cigna, the River Dora and Corso Giulio Cesare. Once known as Borgo del Pallone ('Ball Borough') or Balon in Piedmontese dialect (locally [baˈlun]), this neighbourhood is known for its mercatino del Balon or simply Balon, the Turinese flea market that opens every Saturday in its tiny and twisted streets.
Sources: en.wikipedia.org
Sanger changed his research project to study the metabolism of lysine and a more practical problem concerning the nitrogen of potatoes. His thesis had the title, "The metabolism of the amino acid lysine in the animal body". He was examined by Charles Harington and Albert Charles Chibnall and awarded his doctorate in 1943.
=== Medicine === In medicine, modern biotechnology has many applications in areas such as pharmaceutical drug discoveries and production, pharmacogenomics, and genetic testing (or genetic screening). In 2021, nearly 40% of the total company value of pharmaceutical biotech companies worldwide were active in Oncology with Neurology and Rare Diseases being the other two big applications.
==== Positive selection ==== The process of positive selection takes 3 to 4 days and occurs in the thymic cortex. Double-positive thymocytes (CD4+/CD8+) migrate deep into the thymic cortex, where they are presented with self-antigens. These self-antigens are expressed by thymic cortical epithelial cells on MHC molecules, which reside on the surface of cortical epithelial cells. Only thymocytes that interact well with MHC-I or MHC-II will receive a vital "survival signal", while those that cannot interact strongly enough will receive no signal and die from neglect. This process ensures that the surviving thymocytes will have an 'MHC affinity' that means they will exhibit stronger binding affinity for specific MHC alleles in that organism. The vast majority of developing thymocytes will not pass positive selection, and die during this process. A thymocyte's fate is determined during positive selection. Double-positive cells (CD4+/CD8+) that interact well with MHC class II molecules will eventually become CD4+ "helper" cells, whereas thymocytes that interact well with MHC class I molecules mature into CD8+ "killer" cells. A thymocyte becomes a CD4+ cell by down-regulating expression of its CD8 cell surface receptors. If the cell does not lose its signal, it will continue downregulating CD8 and become a CD4+, both CD8+ and CD4+ cells are now single positive cells. This process does not filter for thymocytes that may cause autoimmunity. The potentially autoimmune cells are removed by the following process of negative selection, which occurs in the thymic medulla.
In 2009, the Justice Department reported that Mexican drug cartels distribute drugs in nearly 200 cities across the United States, including Los Angeles, Chicago, and Atlanta. Gang-related activity and violence has increased along the U.S. Southwest border region, as U.S.-based gangs act as enforcers for Mexican drug cartels. In October 2025, Mexican cartels are issuing bounties up to $50,000 for a hit on ICE and CBP agents according to the Department of Homeland Security.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.